Short answer
What is tirzepatide? Tirzepatide is a synthetic peptide that activates two incretin receptors - the GIP receptor and the GLP-1 receptor - within a single molecule, making it a dual receptor agonist. It is studied in metabolic pathway research as a reference dual agonist. It is sold as a lyophilized research powder and is not for human use.
What is tirzepatide?
Tirzepatide is a dual GIP/GLP-1 receptor agonist. GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) are the two principal incretin hormones - gut-derived peptides that potentiate insulin secretion in response to food intake. Tirzepatide was engineered to combine agonist activity at both receptors in a single molecule, and it was the first compound of this dual-receptor architecture to reach large-scale clinical research [1].
The peptide belongs to the same engineered family as semaglutide (a GLP-1 mono-agonist) and retatrutide (a triple GIP/GLP-1/glucagon agonist). Its defining feature is that it adds GIP receptor activity to the well-characterized GLP-1 receptor axis without adding glucagon receptor activity. Because it engages two receptor systems, it is a common reference tool in research questions about receptor selectivity, incretin signaling, and structure-activity relationships [1][2].
The two incretin receptors
Both GIP and GLP-1 receptors are class B G-protein-coupled receptors that signal through G alpha-s and raise intracellular cyclic AMP, but their biology differs in important ways.
The GLP-1 receptor is expressed on pancreatic beta cells, where it potentiates glucose-stimulated insulin secretion, and on alpha cells, gut, and brain regions that regulate appetite and gastric emptying. It is the target of the largest class of incretin research compounds. The GIP receptor is also expressed on beta cells, where it potentiates insulin secretion, but it has additional expression in adipose tissue, where it has been linked to lipid metabolism, and it is less completely understood than the GLP-1 receptor.
Tirzepatide activates both receptors, so it combines the two incretin pathways in one peptide. A central research question in the field is how GIP receptor agonism modifies the effects of GLP-1 receptor agonism when both are present simultaneously, and tirzepatide is the standard tool for studying that interaction.
Mechanism of action
Tirzepatide is a full agonist at both the GIP and GLP-1 receptors. Binding to each receptor stabilizes its active conformation and initiates G alpha-s signaling, raising cyclic AMP and engaging downstream effectors. In pancreatic beta cells this potentiates glucose-stimulated insulin secretion, so the peptide amplifies the response to elevated glucose rather than triggering insulin release independently.
Two mechanistic points are distinctive for tirzepatide. First, its potency at the two receptors is not equal: the peptide shows high potency at the GIP receptor and somewhat lower potency at the GLP-1 receptor, a profile that differs from the native hormones and is itself a subject of structure-activity research [1]. Second, like other long-acting incretin peptides, tirzepatide carries a fatty-acid modification that binds albumin, slowing clearance and extending its duration of action. The albumin-binding design is shared with semaglutide but the receptor selectivity is different.
GIP receptor biology in research
The GIP receptor is less completely characterized than the GLP-1 receptor, which is one reason dual agonists have attracted research interest: activating a receptor whose biology is still being mapped is itself a scientific question. GIP is released from gut K cells after a meal, and its receptor is expressed on pancreatic beta cells, where GIP potentiates insulin secretion, and on adipose tissue, where GIP receptor signaling has been linked to lipid storage and fatty-acid metabolism. It has also been studied for roles in bone metabolism and the central nervous system.
Because the two receptors engage overlapping but non-identical tissues, a dual agonist does not simply add two independent effects. The interactions between GIP and GLP-1 receptor signaling - in the beta cell, in adipose tissue, and centrally - are the active research frontier. Tirzepatide is the standard reagent for probing those interactions, and a large body of work has asked how much of the compound's overall pharmacology is attributable to the GIP arm versus the GLP-1 arm.
Why dual agonists matter for assay design
Dual agonists let researchers compare single-receptor and dual-receptor signaling within one experiment. A common approach is to run parallel assays with a GLP-1 mono-agonist (such as semaglutide), a GIP mono-agonist, and the dual agonist, then compare receptor activation profiles and downstream readouts. Because tirzepatide is a chemically defined, single-molecule dual agonist, it avoids the confounding factors of mixing two separate peptides, such as unequal stability or different receptor-occupancy kinetics.
For a broader overview of the compound family, see our GLP-1 research peptides buyer's guide and the GLP-1 & metabolic research category. Tirzepatide is also useful as the middle point of the receptor-complexity progression: compare it against semaglutide for the GLP-1 mono-agonist and retatrutide for the triple agonist.
Research background
The clinical research record for tirzepatide is anchored by the SURMOUNT program. The foundational SURMOUNT-1 trial, published in the New England Journal of Medicine in 2022, randomized more than 2,500 adults with obesity to once-weekly tirzepatide at 5 mg, 10 mg, or 15 mg, or placebo, and reported dose-dependent reductions in body weight over 72 weeks, with mean changes ranging from roughly 15% to 21% across the dose groups versus about 3% with placebo [2]. This was the first large trial of a dual GIP/GLP-1 agonist, and it defined the pharmacokinetic and safety profile that now underpins the research literature.
A recurring interpretation question in the field concerns the contribution of each receptor arm. Because the peptide is a single molecule, its effects cannot be decomposed into GIP-specific and GLP-1-specific components simply by inspection; researchers instead use selective antagonists, knockout models, or comparisons against GLP-1 mono-agonists to infer the contribution of each pathway. Tirzepatide is frequently the compound around which these inferential experiments are designed.
For laboratory researchers, this record is background pharmacology. It confirms that tirzepatide is a genuine dual receptor agonist with measurable effects in humans and supports its use as a reference compound in receptor and signaling assays. It does not substitute for primary experimentation; each assay must be validated under its own conditions.
Sequence engineering at a glance
Tirzepatide is a synthetic peptide derived from native GIP with targeted amino-acid changes and a C20 fatty-diacid side chain. The native GIP backbone was selected as the starting point, and several residues were modified to tune receptor selectivity, potency, and metabolic stability. The fatty-diacid moiety binds albumin, extending the peptide's residence time in circulation, in the same design tradition used for semaglutide.
Two engineering features matter most for the researcher. First, the receptor-selectivity profile is a deliberate design outcome: the peptide is a full agonist at both receptors but with higher potency at the GIP receptor than at the GLP-1 receptor, a profile that differs from equimolar mixtures of the native hormones. Second, because the sequence carries non-natural modifications, the theoretical molecular mass is a specific, published value; any deviation in the measured mass indicates a synthesis error. This makes mass-spectrometry identity confirmation the single most important analytical check before use.
How to evaluate research-grade tirzepatide
Because tirzepatide is a large, heavily modified peptide, analytical verification is essential:
See the Tirzepatide product page for an example of the documentation supplied.
Storage and handling
Standard lyophilized-peptide handling applies:
For a detailed step-by-step protocol, see our peptide reconstitution and laboratory handling guide and our peptide storage guide.
Summary
Tirzepatide is a dual GIP/GLP-1 receptor agonist that combines the two incretin pathways in a single molecule. It is the reference dual agonist of the incretin field, used to study how GIP and GLP-1 receptor signaling interact, and it sits between the GLP-1 mono-agonists and the triple agonists in the receptor-complexity progression. Its deliberate receptor-selectivity profile and albumin-binding design make it both a pharmacological research subject and a dependable assay comparator. For laboratories building an incretin compound panel, tirzepatide supplies the critical dual-receptor data point between the GLP-1 mono-agonist and triple-agonist references. As with all research peptides, verify HPLC purity, mass-spectrometry identity, and batch-specific COA, and follow standard lyophilized-peptide handling protocols.
FAQ
What is tirzepatide?
A dual GIP/GLP-1 receptor agonist peptide.
What does dual agonist mean?
One molecule activates two receptors - GIP and GLP-1.
How is it studied?
Receptor pharmacology, cell signaling and metabolic research models.
Is it for human use?
No, laboratory research use only.